Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)

Mar Llamas-Velasco, Mercedes Hospital, Anna López-Ferrer, Pedro Herranz, Ricardo Ruíz-Villaverde, Almudena Mateu, Francisco Javier García-Latasa, Raquel Rivera, Lourdes Rodriguez Fernández-Freire, Elena Del Alcazar, Sergio Santos, Salvador Arias, Alvaro Gónzalez-Cantero, Isabel Belinchon, Gregorio Carretero, Marta Ferran, Diana Ruiz-Genao, Noemí Eiris, Antonio Sahuquillo, Javier Mataix, Jose-María Carrascosa, Pablo de la Cueva, Laura Salgado-Boquete

Open source

DOI: 10.3390/pharmacy14030063
Published: 2026-04-24
Container: Pharmacy
Publisher: MDPI AG
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/pharmacy14030063,
  title = {Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)},
  author = {Mar Llamas-Velasco and Mercedes Hospital and Anna López-Ferrer and Pedro Herranz and Ricardo Ruíz-Villaverde and Almudena Mateu and Francisco Javier García-Latasa and Raquel Rivera and Lourdes Rodriguez Fernández-Freire and Elena Del Alcazar and Sergio Santos and Salvador Arias and Alvaro Gónzalez-Cantero and Isabel Belinchon and Gregorio Carretero and Marta Ferran and Diana Ruiz-Genao and Noemí Eiris and Antonio Sahuquillo and Javier Mataix and Jose-María Carrascosa and Pablo de la Cueva and Laura Salgado-Boquete},
  year = {2026},
  journal = {Pharmacy},
  doi = {10.3390/pharmacy14030063},
  url = {https://doi.org/10.3390/pharmacy14030063}
}

RIS

TY  - JOUR
TI  - Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
AU  - Mar Llamas-Velasco
AU  - Mercedes Hospital
AU  - Anna López-Ferrer
AU  - Pedro Herranz
AU  - Ricardo Ruíz-Villaverde
AU  - Almudena Mateu
AU  - Francisco Javier García-Latasa
AU  - Raquel Rivera
AU  - Lourdes Rodriguez Fernández-Freire
AU  - Elena Del Alcazar
AU  - Sergio Santos
AU  - Salvador Arias
AU  - Alvaro Gónzalez-Cantero
AU  - Isabel Belinchon
AU  - Gregorio Carretero
AU  - Marta Ferran
AU  - Diana Ruiz-Genao
AU  - Noemí Eiris
AU  - Antonio Sahuquillo
AU  - Javier Mataix
AU  - Jose-María Carrascosa
AU  - Pablo de la Cueva
AU  - Laura Salgado-Boquete
PY  - 2026
JO  - Pharmacy
DO  - 10.3390/pharmacy14030063
UR  - https://doi.org/10.3390/pharmacy14030063
ER  -

APA

Llamas-Velasco, M., Hospital, M., López-Ferrer, A., Herranz, P., Ruíz-Villaverde, R., Mateu, A., García-Latasa, F. J., Rivera, R., Fernández-Freire, L. R., Alcazar, E. D., Santos, S., Arias, S., Gónzalez-Cantero, A., Belinchon, I., Carretero, G., Ferran, M., Ruiz-Genao, D., Eiris, N., Sahuquillo, A., Mataix, J., Carrascosa, J., Cueva, P. D. L., & Salgado-Boquete, L. (2026). Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS). Pharmacy. https://doi.org/10.3390/pharmacy14030063

Source records

crossref · retrieved 2026-09-26T17:00:53.595Z